Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services
MWN-AI** Summary
Fortrea, a prominent global contract research organization (CRO) based in Durham, N.C., has expanded its executive team by appointing Oren Cohen, MD, as Chief Medical Officer (CMO) and Scott Dove, PhD, as President of Clinical Pharmacology Services (CPS). This strategic move aims to bolster Fortrea’s medical strategy and enhance its clinical development solutions. Dr. Cohen, the new CMO, will focus on medical strategy, scientific leadership, and oversight of ethics and governance across Fortrea's diverse portfolio, drawing from over 20 years of experience in drug development and leadership roles within the pharmaceutical sector. His impressive background includes prior positions as CMO at Viamet Pharmaceuticals and significant roles at Labcorp Drug Development and Quintiles (now part of IQVIA).
Scott Dove, a seasoned professional with more than 25 years in drug development, takes on the role of President of CPS, overseeing early clinical development solutions across Fortrea’s extensive global network. He brings a wealth of experience from his previous leadership roles at Aravive, PPD, Allergan, and Furiex Pharmaceuticals, alongside a proven track record in clinical operations and drug development.
CEO Anshul Thakral expressed optimism regarding the restructuring, highlighting that Dr. Cohen's focused engagement with clients will enhance scientific collaboration and address complex development challenges, while Dr. Dove's strong technical background will strengthen Fortrea’s offerings in clinical pharmacology.
Fortrea is dedicated to advancing healthcare innovation, partnering with biopharmaceutical and medical device companies to deliver comprehensive clinical trial management across various therapeutic areas. With a commitment to scientific integrity and patient safety, Fortrea aims to continue transforming clinical development and patient care.
MWN-AI** Analysis
Fortrea's recent executive appointments mark a significant strategic move that investors should watch closely. The elevation of Oren Cohen, MD, to a dedicated Chief Medical Officer role alongside the appointment of Scott Dove, PhD, as President of Clinical Pharmacology Services, reflects an organizational commitment to enhancing its clinical development capabilities, which is crucial for a leading contract research organization (CRO).
Dr. Cohen's extensive experience in medical strategy and scientific leadership will enable him to deepen client relationships and enhance engagement in scientific dialogues, crucial for navigating complex clinical challenges while ensuring high standards of patient safety and scientific integrity. His previous roles at Labcorp and Viamet Pharmaceuticals, combined with his medical background, provide Fortrea with a robust leadership platform to bolster its clinical offerings.
Conversely, Scott Dove's appointment brings a wealth of experience from his prior roles in significant biotech and CRO firms, where he has successfully led clinical development operations. His immediate focus on Fortrea's Clinical Pharmacology team suggests potential enhancements in service delivery and innovation within early clinical development solutions – a vital area in the highly competitive CRO market.
From an investment perspective, these leadership changes could signal a transformative period for Fortrea, particularly as the company aims to optimize its clinical trial management processes and consulting services across global markets. The strategic emphasis on enhanced client interaction and technical excellence aligns with broader industry trends favoring personalized patient care and accelerated drug development timelines.
For investors, this could represent an opportune moment to consider Fortrea as a potential holding. If the leadership transition continues to yield innovative advancements in clinical development, Fortrea could leverage its expanded capabilities to gain market share, ultimately enhancing shareholder value. Monitoring the execution of these strategies and their impacts on operational performance will be essential in the coming quarters.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea’s chief medical officer (CMO) and president of Clinical Pharmacology Services (CPS) is now dedicated to his CMO responsibilities, namely medical strategy, scientific leadership, ethics and governance oversight across Fortrea’s portfolio. Scott Dove, PhD joins Fortrea as its new president of CPS, responsible for Fortrea’s early clinical development solutions across its global network of clinical research units. Cohen and Dove both serve on Fortrea’s Executive Committee.
“The addition of Scott to the Fortrea team while Oren becomes fully dedicated to the medical and scientific aspects of development is a win for clients,” said Anshul Thakral, CEO. “Working closely with our business leaders across all phases of clinical development, Oren will deepen his relationships with clients. He’s engaging earlier in scientific dialogue and collaborating closely with our physicians and therapeutic leaders to help address complex development challenges, all while upholding the highest standards of scientific integrity and patient safety. Scott is making a fast start with our Clinical Pharmacology team and is getting a first-hand view of our world-class clinics. He combines a strong technical background in clinical development and operations with a successful track record of leadership in building and leading global organizations, and I’m looking forward to his insights on how we further strengthen our offering.”
Oren Cohen, MD Chief Medical Officer
Oren Cohen, MD is a veteran of drug development, bringing more than 20 years of experience in various medical and scientific executive leadership roles in the pharmaceutical industry. Prior to Fortrea, Dr. Cohen served as CMO and head of Clinical Pharmacology Services at Labcorp Drug Development. Previously, he was CMO at Viamet Pharmaceuticals and served in several senior medical and operational leadership positions at Quintiles, now part of IQVIA.
Dr. Cohen received his MD from Duke University and served his internship and residency at The New York Hospital, Cornell Medical Center in New York City. He completed his fellowship in Infectious Diseases at the National Institute of Allergy and Infectious Diseases, where he stayed as a Principal Investigator and served as the institute's assistant director for medical affairs. He is a Consulting Professor of Medicine at Duke University Medical Center, a member of the Board of Visitors for Duke University School of Medicine and a Fellow of the Infectious Diseases Society of America.
Scott Dove, PhD President Clinical Pharmacology Services
Scott Dove, PhD brings more than 25 years of drug development experience to Fortrea, serving in roles of increasing responsibility at pharma, biotech and CRO companies. Most recently, he has served as an advisor to a variety of companies, including Fortrea. Previously, Dr. Dove was chief operating officer at Aravive, leading R&D operations for a clinical stage, oncology-focused biotech. He also served in leadership roles at PPD for more than a decade, where he led early development services. Dr. Dove also held leadership roles at Allergan and Furiex Pharmaceuticals.
Dr. Dove received his PhD from Texas A&M Health Science Center and earned his bachelor of science in biochemistry at Texas A&M University.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts:
Tracy Krumme (Investors) – 984-385-6707, Tracy.Krumme@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
FAQ**
How will the leadership changes at Fortrea Holdings Inc. (FTRE) impact its strategic focus on early clinical development solutions under Scott Dove's guidance?
2. What specific initiatives is Fortrea Holdings Inc. (FTRE) planning to implement to enhance client relationships following Oren Cohen's full dedication to medical strategy?
3. Can Fortrea Holdings Inc. (FTRE) provide insights into how the expanded executive team will influence its operations in various therapeutic areas?
4. What key performance indicators does Fortrea Holdings Inc. (FTRE) plan to track to measure the success of its new executive leadership structure and its impact on clinical trial management outcomes?
**MWN-AI FAQ is based on asking OpenAI questions about Fortrea Holdings Inc. (NASDAQ: FTRE).
NASDAQ: FTRE
FTRE Trading
1.36% G/L:
$9.66 Last:
746,585 Volume:
$9.90 Open:
